Press release

GENOMICS | DIAGNOSTIC TESTS | GENETICS | R&D

Genomic Vision Expands its Senior Management Team through a Number of Strategic Recruitments

Bagneux, France (January 11, 2016) - Genomic Vision (FR0011799907 – GV), a molecular diagnostics company specializing in the development of diagnostic tests for genetic diseases and cancers based on molecular combing technology, today announces three strategic appointments to its senior management team.

M. Stephane Altaba, PhD., is appointed Vice-President Corporate Development
With a PhD. in biotechnology from the Ecole Nationale Supérieure d’Agronomie et des Industries Alimentaires (ENSAIA) and an MBA in Management (ESCP Europe), Stephane Altaba (50) has over 20 years of experience in strategic positions in pharmaceutical companies. Before joining Genomic Vision, Stephane Altaba was Vice-President Corporate Business Development at Nordic Pharma Group (2006-2015). Prior to that, he was Director Corporate Licenses at Sanofi, where he began his career as a research scientist in 1994 after completing his postdoctoral studies at Riken, the largest life sciences research institution in Japan.

M. Camille Chypre, PhD., is appointed Vice-President R&D
PhD. in cellular and molecular biology (University of Strasbourg) and biochemical engineer (INSA Lyon), Camille Chypre (50) has over 25 years of experience in positions of responsibility in major international diagnosis companies such as Canadian company DiagnoCure (1997-2005) and American company BioRad (2005-2013). Before joining Genomic Vision, Camille Chypre was Executive Vice President at LXRepair.

Mrs. Anne Jacquet, PhD., is appointed Medical Director
PhD. in pharmacology (Mediterranean University, Marseille) and Doctor of Pharmacy (University of Nantes) Anne Jacquet (46), has over 15 years of experience in preclinical and clinical research in the field of cardiovascular disease and oncology. She also has an in-depth knowledge of regulatory procedures in Europe and the United States.

Aaron Bensimon, Genomic Vision’s co-founder and Chairman, concludes: “We are delighted with the arrival of another three acknowledged experts within our senior management team. Their complementarity will be extremely beneficial for Genomic Vision from both a corporate development perspective, through new partnerships, and a clinical perspective, with a number of ongoing key studies.”

Upcoming financial publication

- Annual Revenue for 2015, Monday, January 18, 2016* (after trading)

* indicative date, which may be subject to change
ABOUT GENOMIC VISION

Founded in 2004, Genomic Vision is a molecular diagnostics company that specializes in the development of diagnostic tests for genetic diseases and cancers based on molecular combing. Using this innovative technology that allows the direct visualization of individual DNA molecules, Genomic Vision detects quantitative and qualitative variations in the genome that are at the origin of numerous serious pathologies. The Company is developing a solid portfolio of tests that initially target breast and colon cancers. Since 2013, the Company has marketed the CombHelix FSHD test for identifying facioscapulohumeral dystrophy (FSHD), a myopathy that is difficult to detect. It is marketed in the United States through a strategic alliance with Quest Diagnostics, the American leader in diagnostic laboratory tests, and in France directly by the Company. Genomic Vision has been listed on Compartment C of Euronext Paris since April 2014.

ABOUT MOLECULAR COMBING

DNA molecular combing technology significantly improves the structural and functional analysis of DNA molecules. DNA fibers are stretched over glass slides, as if "combed", and uniformly aligned over the entire surface. It is then possible to identify genetic anomalies by locating specific genes or sequences in the patient's genome using genetic markers, a technique developed by Genomic Vision and patented under the name Genomic Morse Code. This exploration of the entire genome at high resolution via a simple analysis enables the direct visualization of genetic anomalies that are undetectable by other technologies.

For further information, please go to: www.genomicvision.com

CONTACTS

Genomic Vision
Aaron Bensimon
Co-founder, Chairman & CEO
Tel.: +33 1 49 08 07 50
investisseurs@genomicvision.com

LHA
Investor Relations US
Anne Marie Fields, SVP
Tel.: 212-838-3777
afields@lhai.com

NewCap
Investor Relations /
Strategic Communications
Dušan Orešanský / Emmanuel Huynh
Tel.: +33 1 44 71 94 92
gv@newcap.fr

Member of CAC® Mid & Small, CAC® All-Tradable and
EnterNext® PEA-PME 150 indexes